Donate For Public and Patients Store Search

F105 - Managing Melanoma

Sunday, March 3; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize the importance of educating the patient diagnosed with melanoma and in providing a patient-centered informed consent.
  • Formulate a plan for the first step in therapeutic managing melanoma, surgical removal, and distinguish the advantages of the various forms of excision including wide excision and Mohs micrographic excision with MART-1 immunostains.
  • Recognize the choices patients have about adjuvant testing and treatment, and discuss sentinel lymph node biopsy from the standpoint of prognosis and it's therapeutic value


The dermatologist serves an important function in the management of melanoma. Even after diagnosis, the role of the dermatologist is critical in designing an appropriate management plan. Providing informed consent and guidance remains an important part of the dermatologists complete care of the patient. The information provided will enhance the dermatologists ability to counsel regarding appropriate surgical removal, prognostication using Breslow's thickness, and the prognostic and therapeutic value of sentinel lymph node biopsy relative to the clinical situation. Recommended follow-up schedules for melanoma patients based on the pathologic stage will be reviewed.


  • Brodland, David G., MD: no financial relationships exist with commercial interests.
  • Chu, Emily Y., MD, PhD: no financial relationships exist with commercial interests.
  • Etzkorn, Jeremy Robert, MD: no financial relationships exist with commercial interests.
  • Gerami, Pedram, MD: Castle Biosciences, Inc – C(H); DermTech International – C(H); Myriad Genetics Inc – C(H);
  • Kunishige, Joy H., MD: no financial relationships exist with commercial interests.
  • Miller, Christopher James, MD: no financial relationships exist with commercial interests.
  • Zitelli, John A., MD: no financial relationships exist with commercial interests.
Sunday, March 3
3:30 PM
Dr. Brodland / Introduction
3:35 PM
Dr. Kunishige / Excision Margins for Melanoma: Overview and implications
3:50 PM
Dr. Etzkorn / Managing Atypical Melanocytic Proliferations
4:05 PM
Dr. Gerami / Genetic expression profiles for Melanoma: Insights into current and future clinical applications
4:20 PM
Dr. Miller / Challenges in surgery of cutaneous melanoma: Indications for margin control prior to reconstruction
4:35 PM
Dr. Chu / Update on Therapy for Metastatic Melanoma
4:55 PM
Dr. Zitelli / Sentinel Lymph Node Biopsy: Current evidence for its role in managing melanoma
5:15 PM
Dr. Brodland / Guidelines for Follow-up of Melanoma
5:20 PM
All faculty / Q & A
Event Details
  • Date
    Sunday, March 3
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 146B
  • CME Credits
  • Type
  • David G. Brodland, MD, FAAD
  • Christopher James Miller, MD, FAAD - Handout
  • Emily Y. Chu, MD, PhD, FAAD - Handout
  • Jeremy Robert Etzkorn, MD, FAAD
  • John A. Zitelli, MD, FAAD - Handout
  • Joy H. Kunishige, MD, FAAD - Handout
  • Pedram Gerami, MD, FAAD - Handout